The EGF receptor inhibitor gefitinib and HB-EGF neutralizing antibody erase the myofibroblast contribution to tumor growth, progression, migration, and invasion in cholangiocarcinoma in mice. This evidence concerns the gene EGF and cholangiocarcinoma.